HEALTH FOR ALL
through digital health
G4A scales and supports digital health companies through commercial partnerships and investments.
As Europe’s first accelerator by a pharmaceutical company, Bayer has supported over 150 digital health companies, resulting in more than 30 direct collaborations.
Startups since 2014
Total Alumni Value
What our alumni have to say
Dr. Tryggvi Thorngeirsson
“Bayer has always been at the forefront of innovation in disease prevention and management, so we were thrilled to be invited to G4A. There is a tremendous opportunity to empower people to reduce their risk of lifestyle related diseases, and it’s exciting to explore how we can deliver elective tools to help realize that opportunity on a global scale.”
CEO & Co-Founder
The G4A Program provided us with access to and insight from key stakeholders from throughout the Bayer organization and the pharmaceutical industry at large. We were able to dig deep and better understand the corporate structure and the many opportunities for collaboration. Moreover, the expertise offered to us from both a financial modeling, go-to-market strategy and fundraising perspective has made a substantial impact on our current success. Lastly, the G4A team is just hard working and fun to be around, making the program a blast.
“The G4A ecosystem is one of the most important assets in the industry around the world… we have learned a lot of valuable insights and knowledge about the digital health business… We were able to grow our early stage startup into a true healthcare company with partnerships, guidance and financial support from G4A.”
“At Caria, we’re creating a future where women feel supported in every stage of their lives. Our vision is to use data and technology to make a meaningful impact on women’s long-term health”
CEO & Co-Founder
“The G4A program was a transformative experience for Turbine. It was a fantastic opportunity to validate our platform at an early stage... since then, our partnership with Bayer evolved into several exciting collaborations with the promise of breaking new grounds in cancer therapies.”